Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

BACKGROUND: Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate between Alzheimer’s disease and other neurodegenerative diseases. However, these cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Barthélemy, Nicolas R., Bateman, Randall J., Hirtz, Christophe, Marin, Philippe, Becher, François, Sato, Chihiro, Gabelle, Audrey, Lehmann, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079453/
https://www.ncbi.nlm.nih.gov/pubmed/32183883
http://dx.doi.org/10.1186/s13195-020-00596-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079453/
https://www.ncbi.nlm.nih.gov/pubmed/32183883
http://dx.doi.org/10.1186/s13195-020-00596-4

Ejemplares similares